The move follows the company’s rising debt burdens, which has amounted to a total of Rs15bn ($290m).
The company said that the Jammu plant is still under trial for production and has been shut down for now, reports moneycontrol.com.
Surya Pharmaceuticals focuses on contract manufacturing, custom synthesis, FTE research, and marketing of pharmaceuticals products and services to clients across the globe.
The company’s product portfolio includes a range of APIs, fine intermediates, finished drug formulations (FDFs) and phyto pharmaceuticals.